Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission.

[1]  C. Campochiaro,et al.  Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry , 2022, Frontiers in Medicine.

[2]  R. Giacomelli,et al.  Systematic review on the use of biologics in adult-onset still's disease. , 2022, Seminars in arthritis and rheumatism.

[3]  A. Burlui,et al.  Adult-Onset Still’s Disease—A Complex Disease, a Challenging Treatment , 2022, International journal of molecular sciences.

[4]  Q. Lu,et al.  Adult-onset Still’s disease: A disease at the crossroad of innate immunity and autoimmunity , 2022, Frontiers in Medicine.

[5]  Liangjing Lu,et al.  Clinical phenotypes and prognostic factors of adult-onset Still’s disease: data from a large inpatient cohort , 2021, Arthritis Research & Therapy.

[6]  T. Hosoya,et al.  Associated factors with poor treatment response to initial glucocorticoid therapy in patients with adult-onset Still’s disease , 2021, Arthritis Research & Therapy.

[7]  A. Tomelleri,et al.  Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease. , 2021, Clinical and experimental rheumatology.

[8]  S. Çolak,et al.  Biological treatment in resistant adult-onset Still’s disease: A single-center, retrospective cohort study , 2021, Archives of rheumatology.

[9]  D. Foell,et al.  Application of systems biology-based in silico tools to optimize treatment strategy identification in Still’s disease , 2021, Arthritis Research & Therapy.

[10]  P. Sfikakis,et al.  Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients. , 2020, Seminars in arthritis and rheumatism.

[11]  A. Tomelleri,et al.  Drug retention rates of biological agents in adult onset Still's disease. , 2020, Seminars in arthritis and rheumatism.

[12]  C. Campochiaro,et al.  Current treatment options and safety considerations when treating adult-onset Still’s disease , 2020, Expert opinion on drug safety.

[13]  A. Vitale,et al.  Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease , 2020, Mediators of inflammation.

[14]  C. Wouters,et al.  Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study , 2020, Arthritis & rheumatology.

[15]  F. Atzeni,et al.  Parenchymal lung disease in adult onset Still’s disease: an emergent marker of disease severity—characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients , 2020, Arthritis Research & Therapy.

[16]  B. Anić,et al.  Treatment of refractory adult onset Still’s disease with tocilizumab—a single centre experience and literature review , 2020, Rheumatology International.

[17]  G. Bertsias,et al.  AB1041 BIOLOGICS IN ADULT’S ONSET STILL’S DISEASE: TREATMENT STRATEGIES AND SAFETY IN SINGLE CENTER COHORT WITH LONG-TERM FOLLOW-UP , 2020, Annals of the Rheumatic Diseases.

[18]  A. Tomelleri,et al.  FRI0506 EFFICACY AND SAFETY OF CANAKINUMAB IN ADULT-ONSET STILL’S DISEASE: A SINGLE-CENTER REAL-LIFE EXPERIENCE , 2020, Annals of the Rheumatic Diseases.

[19]  L. Sammut,et al.  EP18 Use of anakinra for haemophagocytic lymphohistiocytosis in adults , 2020 .

[20]  G. Cavalli,et al.  Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes , 2020, Frontiers in Medicine.

[21]  I. Yokota,et al.  Calcineurin inhibitors for adult-onset Still's disease: a multicentre retrospective cohort study. , 2020, Clinical and experimental rheumatology.

[22]  L. Dagna,et al.  Management of adult-onset Still’s disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts , 2019, Arthritis Research & Therapy.

[23]  F. Atzeni,et al.  Prescribing motivations and patients’ characteristics related to the use of biologic drugs in adult-onset Still’s disease: analysis of a multicentre “real-life” cohort , 2019, Rheumatology International.

[24]  D. Foell,et al.  Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study , 2019, Arthritis & rheumatology.

[25]  G. Cavalli,et al.  Long-Term Retention Rate of Anakinra in Adult Onset Still’s Disease and Predictive Factors for Treatment Response , 2019, Front. Pharmacol..

[26]  G. Guggino,et al.  Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study , 2019, Medicine.

[27]  T. Barnetche,et al.  Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy , 2019, Arthritis Research & Therapy.

[28]  E. Feist,et al.  Mechanisms, biomarkers and targets for adult-onset Still’s disease , 2018, Nature Reviews Rheumatology.

[29]  Y. Shoenfeld,et al.  A comprehensive review on adult onset Still's disease. , 2018, Journal of autoimmunity.

[30]  N. Okiyama,et al.  Evidence-based clinical practice guideline for adult Still’s disease , 2018, Modern rheumatology.

[31]  H. Fang,et al.  Biological therapy of traditional therapy-resistant adult-onset Still’s disease: an evidence-based review , 2018, Therapeutics and clinical risk management.

[32]  D. Rossi,et al.  How I treat patients with adult onset Still's disease in clinical practice. , 2017, Autoimmunity reviews.

[33]  G. De Sarro,et al.  Biologic drugs in adult onset Still’s disease: a systematic review and meta-analysis of observational studies , 2017, Expert review of clinical immunology.

[34]  L. Punzi,et al.  Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still’s Disease: A Multicentre Retrospective Observational Study , 2017, Front. Pharmacol..

[35]  K. Amano,et al.  THU0577 Tocilizumab monotherapy for adult onset still's disease – results of 52-week treatment of a prospective, single-center, single-arm, open trial , 2017 .

[36]  G. Ferraccioli,et al.  Refractory adult-onset Still disease complicated by macrophage activation syndrome and acute myocarditis , 2017, Medicine.

[37]  M. Valenti,et al.  Adult-onset Still’s disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers , 2016, BMC Medicine.

[38]  H. Kato,et al.  Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease Successfully Treated with Anakinra , 2016, Case reports in rheumatology.

[39]  M. Inanç,et al.  FRI0502 Biologic Agents in Refractory Adult Still's Disease: Better Response Rates and Acceptable Safety with Anakinra and Tocilizumab , 2016 .

[40]  Q. Yao,et al.  Macrophage activation syndrome complicating adult onset Still's disease: A single center case series and comparison with literature. , 2016, Seminars in arthritis and rheumatism.

[41]  S. Bombardieri,et al.  Adult-onset Still’s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients , 2016, Clinical Rheumatology.

[42]  D. Solmaz,et al.  Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: Data from a large multicenter cohort. , 2016, Journal of autoimmunity.

[43]  F. Vandergheynst,et al.  Efficacy of Low-Dose Tocilizumab on Relapsing Adult-Onset Still's Disease. , 2016, Acta medica.

[44]  C. Campochiaro,et al.  Efficacy and safety of biological agents in adult-onset Still’s disease , 2015, Scandinavian journal of rheumatology.

[45]  S. Castañeda,et al.  SAT0525 Tocilizumab Compared with Anakinra in Refractory Adult-Onset Still's Disease. Multicenter Study of 75 Patients , 2015 .

[46]  P. Sève,et al.  Adult-onset Still's disease. , 2014, Autoimmunity reviews.

[47]  S. Castañeda,et al.  THU0390 Efficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Open-Label Study of 34 Patients , 2014 .

[48]  J. Ablin,et al.  Tocilizumab in Adult-onset Still’s Disease: the Israeli Experience , 2014, The Journal of Rheumatology.

[49]  P. Efthimiou,et al.  THU0401 Successful use of canakinumab in adult-onset still’s disease refractory to short acting IL-1 inhibitors , 2013 .

[50]  Z. Amoura,et al.  Anakinra in Adult‐Onset Still's Disease: Long‐Term Treatment in Patients Resistant to Conventional Therapy , 2013, Arthritis care & research.

[51]  C. Suh,et al.  Therapeutic responses and prognosis in adult-onset Still’s disease , 2012, Rheumatology International.

[52]  J. Nolla,et al.  Adult onset Still's disease: review of 41 cases. , 2011, Clinical and experimental rheumatology.

[53]  E. Baldissera,et al.  Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. , 2010, Arthritis and rheumatism.

[54]  Chengde Yang,et al.  Clinical Features and Prognosis of Adult-onset Still’s Disease: 61 Cases from China , 2009, The Journal of Rheumatology.

[55]  H. Inoue,et al.  Cyclosporin A treatment for Japanese patients with severe adult-onset Still’s disease , 2009, Modern rheumatology.

[56]  J. Sibilia,et al.  Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France , 2007, Annals of the rheumatic diseases.

[57]  V. Joshi,et al.  Adult onset Still’s disease: a study of 14 cases , 2007, Clinical Rheumatology.

[58]  M. Boers,et al.  Keeping up appearances , 2002, Annals of the rheumatic diseases.

[59]  O. Meyer,et al.  Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. , 1999, The Journal of rheumatology.

[60]  A. Marchesoni,et al.  Cyclosporin A in the treatment of adult onset Still's disease. , 1997, The Journal of rheumatology.

[61]  R. Priori,et al.  Adult-onset Still's disease: not always so good. , 2012, Clinical and experimental rheumatology.

[62]  이종석,et al.  Adult Onset Still`s Disease (AOSD) , 1999 .